MedTrace Logo

Evaluation of PHP-201 Ophthalmic Solution in Patients With Normal Tension Glaucoma

NCT03106532 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2018-10-26

No results posted yet for this study

Summary

Evaluation of the optimal dose for the efficacy in reduction of intraocular pressure and safety of PHP-201 ophthalmic solution in patients with normal tension glaucoma

Conditions

  • Normal Tension Glaucoma

Interventions

DRUG

PHP-201 0.25% ophthalmic solution

3 drops daily, 28 days

DRUG

PHP-201 0.5% ophthalmic solution

3 drops daily, 28 days

DRUG

Placebo ophthalmic solution

3 drops daily, 28 days

Sponsors & Collaborators

  • pH Pharma

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-06
Primary Completion
2018-05-02
Completion
2018-05-02

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03106532 on ClinicalTrials.gov